I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Box IDS, Assistant Commissioner for Patents, Washington, D.C., 20231 on January 11, 2002

Attorney Docket No.: 019957-013821

RECEIVED

FEB 0 5 2002 TECH CENTER 1600, 2000

TOWNSEND and TOWNSEND and CREW LLP aren Donino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Shawn DeFrees et al.

Application No.: 09/757,289

Filed: January 8, 2001

For: LOW COST MANUFACTURE OF

OLIGOSACCHARIDES

Not Yet Assigned Examiner:

1652 Art Unit:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97 and

§1.98

**BOX IDS Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

The references cited on attached forms PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 09/442,111, filed November 17, 1999 (Attorney Docket No. 019957-013820US). Also enclosed is a copy of the Search/Examination report corresponding to the PCT application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Shawn DeFrees *et al.* Application No.: 09/757,289

Page 2

Applicants believe that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Kevin L. Bastrai

Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

KLB/BLK

SF 1304543 v1

Please type a plus sign (+) inside this box

Under the Paperwork Re

Approved for use through 10 31 2002 OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE ns are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A PTO

## INFORMATION DISCLOSURE STATEMENT BY APRI

(use as many sheets as necessary)

3 of Sheet

|                        | Complete if Known    |
|------------------------|----------------------|
| Application Number     | 09/757,289           |
| Filing Date            | January 8, 2001      |
| First Named Inventor   | Shawn DeFrees et al. |
| Group Art Unit         | 1652                 |
| Examiner Name          | Unassigned           |
| Attorney Docket Number | 019957-013821US      |

|                        |             |  | U.S. PATENT DOCU                                | MENTS  |  |
|------------------------|-------------|--|---|--|--|
| Examiner<br>Initials * | Cite<br>No. | U.S. Patent Document  Kind Code <sup>2</sup> Number (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of<br>Cited Document<br>MM-DD-YYYY | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |
|                        | AA          | 5,705,367  | Gotschlich                                      | Jan. 6, 1998   |  |
|                        | AB          | 5,798,233  | Gotschlich                                      | Aug. 25, 1998  |  |
|                        | AC          | 5,541,083  | Paulson et al.                                  | Jul. 30, 1996  |  |
|                        | AD          | 5,922,577  | DeFrees et al.                                  | Jul. 13, 1999  |  |
|                        | AE          | 5,945,314  | Prieto et al.                                   | Aug. 31, 1999<br>Sept. 10, 1991                        |  |
|                        | AF          | 5,047,335  | Paulson et al.                                  | Зери тол тээт  |  |

|                    |              |                     | FORE                 | IGN PATENT DOCL  | JMENIS                                | Pages, Columns, Lines,              | Γ  |
|--------------------|--------------|---------------------|----------------------|------------------|---------------------------------------|-------------------------------------|----|
|                    |              | Fo                  | eign Patent Document | Name of Patentee | Date of Publication of Cited Document | Where Relevant Passages or Relevant | ٠, |
| Examiner Initials* | Cite<br>No.1 | Office <sup>3</sup> | Number Kind Cod      | an i Designant   | MM-DD-YYYY                            | Figures Appear                      |    |
|                    | AG           | PCT                 | WO 98/44145          | Prieto           | Oct. 8, 1998                          |                                     | No |
|                    | AH           | EPO.                | EP 0870841 A1        | Koizumi          | Oct. 14, 1998                         |                                     | No |
|                    | AI           | EPO                 | EP 0861902 A1        | Koizumi          | Sep. 2, 1998                          |                                     | No |

| Examiner<br>Signature | Date<br>Considered |  |
|-----------------------|--------------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any burden nour Statement. This form is estimated to take 2 o nours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents. Washington. DC 20231

Unique citation designation number \* See attached Kinds of U.S. Patent Documents \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3) <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached

Please type a plus sign (+) inside this box

Approved for use through 10:31:2002 OMB 0651-0031 U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no per ons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B-PTO

STATEMENT BY ARPL

JAN 3 1 2002 INFORMATION DISCLOSUR

Complete if Known 09/757,289 **Application Number** January 8, 2001 Filing Date Shawn DeFrees et a First Named Inventor

(use as many sheets as necessary)

1652 Group Art Unit Unassigned Examiner Name

019957-013821US Attorney Docket Number of Sheet

|                        |              | OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS   | 5.  |
|------------------------|--------------|---|-----|
| Examiner<br>Initials * | Cite<br>No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.           | T   |
| ITITICAL               | AJ           | Endo et al., "Large-scale production of N-acetyllactosamine through bacterial coupling," Carbohydrate Res. 316:179-183 (1999).  |     |
|                        | AK           | Koizumi et al., "Large-scale production of UDP-galactose and globotriose by coupling metabolically engineered bacteria," <i>Nature Biotech.</i> 16:847-850 (1998).  |     |
|                        | AL           | Vimr and Troy, "Regulation of Sialic Acid Metabolism in <i>Escherichia coli</i> : Role of N-Acylneuraminate Pyruvate-Lyase," <i>J. Bacteriol</i> . Vol. 164, No. 2, 854-860 (1985).   |     |
|                        | AM           | Mergaert <i>et al.</i> , "The nodulation gene <i>nolK</i> of <i>Azorhizobium caulinodans</i> is involved in the formation of GDP-fucose from GDP-mannose," <i>FFBS Letters</i> 409:312-316 (1997).  | _   |
|                        | AN           | Gonzales-Clemente <i>et al.</i> , "High Production of polysialic Acid [Neu5Aca(2-8)-Neu5Aca(2-9] <sub>n</sub> by <i>Escherichia coli</i> K92 Grown in a Chemically Defined Medium," <i>Biol. Chem. Hoppe-Seyler</i> , Vol. 371, pp. 1101-1106 (1990).                     |     |
|                        | AO           | Cho and Troy II, "Polysialic acid engineering: Synthesis of polysialylated neoglycosphingolipids by using the polysialyltransferase from neuroinvasive <i>Escherichia coli</i> K1," <i>Proc. Natl. Acad. Sci. USA</i> 91:11427-11431 (1994).                              | 1   |
|                        | AP           | Williams and Wimpenny, "Extracellular Polysaccharide Biosynthesis by <i>Pseudomonas</i> NCIB 11264. Studies on Precursor-forming Enzymes and Factors Affecting Exopolysaccharide Production by Washed Suspensions," <i>J. of Gen. Microbiol.</i> 116:133-141 (1980)       |     |
|                        | AQ           | Mengin-Lecreulx <i>et al.</i> , "Pool Levels of UDP <i>N</i> -Acetylglucosamine and UDP <i>N</i> -Acetylglucosamine-Enolpyruvate in <i>Escherichia coli</i> and Correlation with Peptidoglycan Synthesis," <i>J. of Bacteriology</i> , Vol. 154, No. 3, 1284-1290 (1983). |     |
|                        | AR           | Lloret et al., "Genetic analysis of the transcriptional arrangement of Azotobacter vinelandii alginate biosynthetic genes: identification of two independent promoters," Macrobiol. 21(3):449-457 (1996).   |     |
|                        | AS           | Lindahl et al., "Regulated Diversity of Heparan Sulfate," J. Biol. Chem. 273(39):24979-24982 (1998).  |     |
|                        | AT           | Zacharek <i>et al.</i> , "Bacteria Targeted by Human Natural Antibodies Using α-Gal Conjugated Receptor-Specific Glycopolymers," <i>Bioorg. Med. Chem.</i> 7:1549-1558 (1999)   | )). |

| Examiner  | Date       |
|-----------|------------|
| Signature | Considered |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Washington, DC 20231 SF 1304543 v1



<sup>\*</sup>EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

Unique citation designation number.  $^2$  Applicant is to place a check mark here if English language Translation is attached

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

MAL INFORMATION DISC

Complete if Known 09/757,289 **Application Number** January 8, 2001 Filing Date

(use as many sheets as necessary)

of Sheet

STATEMENT BY APPI

| I mily Date            | January 0, 2001      |           |
|------------------------|----------------------|-----------|
| First Named Inventor   | Shawn DeFrees et al. | $\bar{c}$ |
| Group Art Unit         | 1652                 | 7         |
| Examiner Name          | Unassigned           |           |
| Attorney Docket Number | 019957-013821US      |           |

|                     |              | OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS   | 00  |
|---------------------|--------------|---|-----|
| Examiner Initials * | Cite<br>No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.           | T 2 |
|                     | AU           | Wang <i>et al.</i> , "Enhanced Inhibition of Human anti-Gal Antibody Binding to Mammalian Cells by Synthetic α–Gal Epitope Polymers., <i>J. Amer. Chem. Soc.</i> , 121(36):8174-8181 (1999).  |     |
|                     | AV           | Kawaguchi et al., "An Improved Method for the Fermentative Production of GDP-mannose from 5'-GMP'," J. Ferment. Tech. 49(3):195-201 (1971)  |     |
|                     | AW           | Kawaguchi <i>et al.</i> , "Studies on Microbial Metabolisms of Sugar Nucleotides, Part V., "Effects of Various Factors on the Fermentative Production of GDP-mannose, GDP and GTP from 5'-GMP by Air dried Cells of Baker's Yeast," Agr. Biol. Chem 34(6):908-918 (1970). |     |
|                     | AX           | Janczuk et al., "Alpha-Gal oligosaccharides: chemistry and potential biomedical application," Curr. Med. Chem. 6(2):155-64 (1999)   |     |
|                     | AY           | Gilbert <i>et al.</i> , "The synthesis of sialylated oligosaccharides using a CMP-Neu5Ac synthetase/sialyltransferase fusion," <i>Nat. Biotech.</i> 16:769-772 (1998).  |     |

| Examiner  | Date       |  |
|-----------|------------|--|
| Signature | Considered |  |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SF 1304543 v1

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.